We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Test Screens for Severe Disorders Affecting Newborns

By LabMedica International staff writers
Posted on 26 May 2010
A genetic test screens for some of the most common and severe genetic disorders affecting newborns in pan-ethnic populations.

Designed by a team of geneticists and genetic counselors with many years of clinical and laboratory experience, AmbryScreen is a responsible and ethical method of identifying individuals at high risk of having a child with severe genetic conditions.

Ambry Genetics (Aliso Viejo, CA, USA) introduced AmbryScreen at the American College of Obstetricians and Gynecologists annual clinical meeting in San Francisco (CA, USA) between May 15—19, 2010. More...
The assay screens for over 90 childhood onset conditions and is performed by Ambry Genetics. The core of the test is the most sensitive cystic fibrosis (CF) carrier mutation panel on the market.

The assay was designed by coupling the public databases of information with Ambry's database of over 25,000 patients sequenced during the last decade. The 100 CF mutation panel includes only well-defined disease causing mutations, without containing mild CF mutations like some currently used tests.

Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory. It has become a leader in providing genetic services focused on clinical diagnostics and genomic services.

Related Links:
Ambry Genetics
College of American Pathologists


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.